For the Inventor, By the Inventor

Enter assignee name

Cambridge, United Kingdom

Medimmune Limited

USPTO Granted Patents = 548

% Expired Patents = 32.7

CIPO Patents = 43

EPO Patents = 232

Trademarks = 7

Forward Citations = 5,743

Loading Chart...

Loading Chart...

777 inventors (with patents filed for the assignee):

Philip Wilson Howard (65 out of 92 patents)

George William Kemble (38 out of 41 patents)

Leslie Sydnor Johnson (33 out of 128 patents)

4. Herren Wu (32 out of 50 patents)

5. Changshou Gao (30 out of 32 patents)

6. Ralph Raymond Minter (30 out of 32 patents)

7. William Dall'Acqua (22 out of 22 patents)

8. Patricius Hendrikus Cornelis Van Berkel (21 out of 24 patents)

9. Hong Jin (21 out of 24 patents)

10. Melissa Marie Damschroder (21 out of 26 patents)

11. Scott A Hammond (19 out of 19 patents)

12. Scott Koenig (19 out of 58 patents)

13. Chin-Fen Yang (19 out of 19 patents)

14. Partha S Chowdhury (18 out of 31 patents)

15. Nicole Kallewaard-LeLay (16 out of 19 patents)

Core Competencies:

Bispecific Binding Proteins

Anti-Influenza Antibodies

Cancer Treatment

Polypeptides

Therapeutic Binding Molecules

Combination Therapies

Antibody-Drug Conjugates

RSV-Specific Antibodies

Amyloid Beta Antibodies

Neurodegenerative Disease Treatments

GDF-15 Antibodies

CD73 Binding Molecules

548 patents: Sort by Forward Citations

1. 12758651 - Compositions and methods for delivering pharmaceutically active agents (2026-10-13),

2. 12758644 - PEPTIDE DENDRONS AND METHODS OF USE THEREOF (2026-10-13),

3. 12715933 - MOLECULES WITH ALTERED NEONATE FC RECEPTOR BINDING HAVING ENHANCED THERAPEUTIC AND DIAGNOSTIC PROPERTIES (2026-08-25),

4. 12686718 - TARGETED BINDING AGENTS AGAINST B7-H1 (2026-07-21),

5. 12630648 - BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF (2026-05-19),

6. 12630600 - GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY (2026-05-19),

7. 12570744 - BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEREOF (2026-03-10),

8. 12466874 - Prevention of protein disulfide bond reduction (2025-11-11),

9. 12428473 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2025-09-30),

10. 12391768 - Antibodies to ticagrelor and methods of use (2025-08-19),

11. 12371464 - Polypeptides and uses thereof (2025-07-29),

12. 12357692 - Method of treating influenza A (2025-07-15),

13. 12344664 - Antibodies to amyloid beta (2025-07-01),

14. 12325740 - Neutralizing anti-influenza B antibodies and uses thereof (2025-06-10),

15. 12312397 - Anti-O2 antibodies and uses thereof (2025-05-27),

Company Overview

Medimmune Limited, based in Cambridge, UK, specializes in the development of innovative immunotherapy antibodies aimed at treating various diseases, including cancer and viral infections. The company focuses on advanced therapeutic modalities such as bispecific binding proteins, antibody-drug conjugates, and combination therapies. With a strong emphasis on research in anti-influenza and RSV-specific antibodies, Medimmune is dedicated to creating effective therapeutic solutions that address unmet medical needs in the field of immunology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

548 Patents

#2 in Cambridge

#26 in United Kingdom

#1,773 in the World

Cambridge, United Kingdom

Medimmune Limited

Forward Citations = 5,743

777 inventors:

Philip Wilson Howard (65 out of 92 patents)

George William Kemble (38 out of 41 patents)

Leslie Sydnor Johnson (33 out of 128 patents)

4. Herren Wu (32 out of 50 patents)

5. Changshou Gao (30 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medimmune Limited. Retrieved from https://idiyas.com/company/medimmune

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…